84 related articles for article (PubMed ID: 15136437)
1. Role of p63 amplification and overexpression in lung cancer development.
Massion PP; Taflan PM; Rahman SM; Yildiz P; Shyr Y; Carbone DP; Gonzalez AL
Chest; 2004 May; 125(5 Suppl):102S. PubMed ID: 15136437
[No Abstract] [Full Text] [Related]
2. P63 expression in lung carcinoma: a tissue microarray study of 408 cases.
Au NH; Gown AM; Cheang M; Huntsman D; Yorida E; Elliott WM; Flint J; English J; Gilks CB; Grimes HL
Appl Immunohistochem Mol Morphol; 2004 Sep; 12(3):240-7. PubMed ID: 15551738
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of p63 expression in lung cancer by use of complementary DNA and tissue microarray].
Yu YW; Garber ME; Schlüns K; Pacyna-Gengelbach M; Petersen I
Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):324-7. PubMed ID: 15363316
[TBL] [Abstract][Full Text] [Related]
4. The role of p63 and deltaNp63 (p40) protein expression and gene amplification in esophageal carcinogenesis.
Geddert H; Kiel S; Heep HJ; Gabbert HE; Sarbia M
Hum Pathol; 2003 Sep; 34(9):850-6. PubMed ID: 14562279
[TBL] [Abstract][Full Text] [Related]
5. S100A2 is strongly expressed in airway basal cells, preneoplastic bronchial lesions and primary non-small cell lung carcinomas.
Smith SL; Gugger M; Hoban P; Ratschiller D; Watson SG; Field JK; Betticher DC; Heighway J
Br J Cancer; 2004 Oct; 91(8):1515-24. PubMed ID: 15467767
[TBL] [Abstract][Full Text] [Related]
6. Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders.
Glickman JN; Yang A; Shahsafaei A; McKeon F; Odze RD
Hum Pathol; 2001 Nov; 32(11):1157-65. PubMed ID: 11727253
[TBL] [Abstract][Full Text] [Related]
7. TP53 mutations, amplification of P63 and expression of cell cycle proteins in squamous cell carcinoma of the oesophagus from a low incidence area in Western Europe.
Tanière P; Martel-Planche G; Saurin JC; Lombard-Bohas C; Berger F; Scoazec JY; Hainaut P
Br J Cancer; 2001 Sep; 85(5):721-6. PubMed ID: 11531258
[TBL] [Abstract][Full Text] [Related]
8. High-resolution genomic profiles of human lung cancer.
Tonon G; Wong KK; Maulik G; Brennan C; Feng B; Zhang Y; Khatry DB; Protopopov A; You MJ; Aguirre AJ; Martin ES; Yang Z; Ji H; Chin L; Depinho RA
Proc Natl Acad Sci U S A; 2005 Jul; 102(27):9625-30. PubMed ID: 15983384
[TBL] [Abstract][Full Text] [Related]
9. p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas?
Pelosi G; Pasini F; Olsen Stenholm C; Pastorino U; Maisonneuve P; Sonzogni A; Maffini F; Pruneri G; Fraggetta F; Cavallon A; Roz E; Iannucci A; Bresaola E; Viale G
J Pathol; 2002 Sep; 198(1):100-9. PubMed ID: 12210069
[TBL] [Abstract][Full Text] [Related]
10. Differential expression of p63 isoforms in normal tissues and neoplastic cells.
Nylander K; Vojtesek B; Nenutil R; Lindgren B; Roos G; Zhanxiang W; Sjöström B; Dahlqvist A; Coates PJ
J Pathol; 2002 Dec; 198(4):417-27. PubMed ID: 12434410
[TBL] [Abstract][Full Text] [Related]
11. Homozygous deletions at chromosome 9p21 and mutation analysis of p16 and p15 in microdissected primary non-small cell lung cancers.
Packenham JP; Taylor JA; White CM; Anna CH; Barrett JC; Devereux TR
Clin Cancer Res; 1995 Jul; 1(7):687-90. PubMed ID: 9816033
[TBL] [Abstract][Full Text] [Related]
12. AIS is an oncogene amplified in squamous cell carcinoma.
Hibi K; Trink B; Patturajan M; Westra WH; Caballero OL; Hill DE; Ratovitski EA; Jen J; Sidransky D
Proc Natl Acad Sci U S A; 2000 May; 97(10):5462-7. PubMed ID: 10805802
[TBL] [Abstract][Full Text] [Related]
13. Significance of p63 amplification and overexpression in lung cancer development and prognosis.
Massion PP; Taflan PM; Jamshedur Rahman SM; Yildiz P; Shyr Y; Edgerton ME; Westfall MD; Roberts JR; Pietenpol JA; Carbone DP; Gonzalez AL
Cancer Res; 2003 Nov; 63(21):7113-21. PubMed ID: 14612504
[TBL] [Abstract][Full Text] [Related]
14. Cytology applications of p63 and TTF-1 immunostaining in differential diagnosis of lung cancers.
Wu M; Szporn AH; Zhang D; Wasserman P; Gan L; Miller L; Burstein DE
Diagn Cytopathol; 2005 Oct; 33(4):223-7. PubMed ID: 16138374
[TBL] [Abstract][Full Text] [Related]
15. Maspin expression is transactivated by p63 and is critical for the modulation of lung cancer progression.
Kim S; Han J; Kim J; Park C
Cancer Res; 2004 Oct; 64(19):6900-5. PubMed ID: 15466179
[TBL] [Abstract][Full Text] [Related]
16. Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients.
Liu D; Huang CL; Kameyama K; Hayashi E; Yamauchi A; Sumitomo S; Yokomise H
Cancer; 2002 Apr; 94(8):2239-47. PubMed ID: 12001123
[TBL] [Abstract][Full Text] [Related]
17. Loss of FHIT function in lung cancer and preinvasive bronchial lesions.
Sozzi G; Pastorino U; Moiraghi L; Tagliabue E; Pezzella F; Ghirelli C; Tornielli S; Sard L; Huebner K; Pierotti MA; Croce CM; Pilotti S
Cancer Res; 1998 Nov; 58(22):5032-7. PubMed ID: 9823304
[TBL] [Abstract][Full Text] [Related]
18. A lack of prognostic significance regarding DeltaNp63 immunoreactivity in lung cancer.
Iwata T; Uramoto H; Sugio K; Fujino Y; Oyama T; Nakata S; Ono K; Morita M; Yasumoto K
Lung Cancer; 2005 Oct; 50(1):67-73. PubMed ID: 15950316
[TBL] [Abstract][Full Text] [Related]
19. p63 immunostaining in destained bronchoscopic cytological specimens.
Shtilbans V; Szporn AH; Wu M; Burstein DE
Diagn Cytopathol; 2005 Apr; 32(4):198-203. PubMed ID: 15754365
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of epidermal growth factor receptor signaling decreases p63 expression in head and neck squamous carcinoma cells.
Matheny KE; Barbieri CE; Sniezek JC; Arteaga CL; Pietenpol JA
Laryngoscope; 2003 Jun; 113(6):936-9. PubMed ID: 12782800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
